The early phase advantage: the key to de-risking your clinical trials
In drug development, the earliest phases carry both the greatest uncertainty and the greatest opportunity. Early phase clinical trials, whether…
Analysis
PALSONIFY (paltusotine) for the Treatment of Acromegaly, USA
Multiple sclerosis: three trials to watch
‘The time of the Einsteins is over’: Pharma urged to rethink trials for 2050
Pharma R&D set to endure despite rising MFN costs
Europe’s path to maintaining clinical trial hotbed of innovation
Advancing patient registries and expanding real world evidence through technology
OS endpoint focus will realign industry to “ultimate goal”
